Replies to post #93782 on Biotech Values

[mcbio]

Re: MNTA/M118

The primary end point occurred in 31.1% of patients randomized to UFH and in 22.7%, 28.3%, and 30.1% of patients randomized to M118 50, 75, and 100 IU/kg, respectively.

It appears that there is a pretty clear dose-response relationship with respect to M118. Is it expected that MNTA or, more likely, a partner will test M118 at doses above the 100 IU/kg level in an upcoming Phase 2b trial to see if M118 can produce even better results?

[ghmm]

Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary
intErvention (EMINENCE) Trial

Just happened to be looking and saw the full paper is freely available now for those interested:
http://circ.ahajournals.org/cgi/content/full/121/15/1713